Please use this identifier to cite or link to this item: http://dspace.hmtu.edu.vn/handle/DHKTYTHD_123/383
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGribben, John G.-
dc.contributor.authorRiches, John C.-
dc.date.accessioned2015-11-30T04:21:23Z-
dc.date.available2015-11-30T04:21:23Z-
dc.date.issued2013-
dc.identifier.urihttp://220.231.117.85:8000/handle/DHKTYTHD_123/383-
dc.description.abstractAlthough there have been recent advances with targeted therapies in chronic lymphocytic leukemia (CLL), chemoimmunotherapy remains the treatment of choice; however, this approach is not curative. A key feature of CLL is that it induces a state of immunosuppression, causing increased susceptibility to infections and failure of an antitumor immune response, often worsened by the immunosuppressive effect of treatment. Because of its improved specificity, immunotherapy potentially offers a way out of this dilemma. Allogeneic stem cell transplantation remains the only curative option, but is hampered by the toxicity of GVHD. After many years of promise but little reward, many other immunotherapeutic approaches are now in transition to the clinical setting. Clinical trials including CLL vaccines, CXCR4 antagonists, and adoptive cellular immunotherapies such as chimeric antigen receptor–modified T cells, CD40 ligand gene therapy, and the immunomodulatory drug lenalidomide are ongoing. Results to date suggest that immunotherapeutic approaches for the treatment of CLL might finally be fulfilling their promise.vi
dc.language.isoenvi
dc.publisherAmerican Society of Hematologyvi
dc.titleImmunotherapeutic strategies including transplantation: eradication of diseasevi
dc.typeArticlevi
Appears in CollectionsHuyết học = Hematology

Files in This Item:
File Description SizeFormat 
Hematology-2013-Gribben-151-7.pdf
  Restricted Access
435.56 kBAdobe PDFThumbnail
 Request Item


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.